Gabelli Funds LLC Acquires New Stake in Invitae Corporation (NVTA)
Gabelli Funds LLC acquired a new stake in shares of Invitae Corporation (NYSE:NVTA) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 14,000 shares of the medical research company’s stock, valued at approximately $131,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Verity Asset Management Inc. raised its position in shares of Invitae Corporation by 0.8% during the second quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock valued at $101,000 after buying an additional 81 shares during the last quarter. Lakeview Capital Partners LLC acquired a new position in shares of Invitae Corporation during the third quarter valued at about $117,000. Donald L. Hagan LLC raised its position in shares of Invitae Corporation by 30.0% during the second quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock valued at $124,000 after buying an additional 3,000 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in Invitae Corporation in the third quarter worth about $133,000. Finally, CAPROCK Group Inc. acquired a new position in Invitae Corporation in the third quarter worth about $139,000. 58.00% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.watchlistnews.com/gabelli-funds-llc-acquires-new-stake-in-invitae-corporation-nvta/1706855.html.
Invitae Corporation (NYSE:NVTA) opened at $8.25 on Thursday. Invitae Corporation has a 52-week low of $5.76 and a 52-week high of $11.88. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.61 and a quick ratio of 4.39.
Several research analysts recently issued reports on the stock. BidaskClub raised shares of Invitae Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of Invitae Corporation from a “hold” rating to a “strong-buy” rating and set a $11.00 price target for the company in a research report on Wednesday, October 11th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $15.00 price target (up previously from $14.00) on shares of Invitae Corporation in a research report on Wednesday, August 9th. Finally, Leerink Swann dropped their price target on shares of Invitae Corporation from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $13.50.
Invitae Corporation Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for Invitae Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.